The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Inflammation and ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) is a highly lethal gynecological cancer for which overall prognosis has remained poor over the past few decades. A number of theories have been postulated in an effort to explain the etiology of EOC. Noteworthy, these theories likely are not mutually exclusive, as they all converge more or less on the role of inflammation in promoting ovarian tumorigenesis and cancer progression. The tumor milieu in which ovarian carcinoma develops has been described as one enriched with a broad spectrum of pro-inflammatory cytokines and chemokines. In particular, several of these cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, produced by tumor itself or/and activated immune cells, besides stimulating cancer cell growth, have been shown to influence clinical disease status and prognosis, by reducing responsiveness to chemotherapy and inducing symptoms such as anorexia, altered energy metabolism, anemia, weight loss, depression and fatigue. Recent data show that cytokine antagonists may have a role to play in the treatment of ovarian cancer. Their action by inhibiting both production and activity of inflammatory cytokines seems to obtain the control of angiogenetic and apoptotic events, the reversal of chemoresistance, the improvement of systemic symptoms and prognosis. In the light of our scientific research and the most recent experimental and clinical advances, our review will discuss the most relevant and recent findings on the role of proinflammatory cytokines in the pathogenesis and prognosis of ovarian cancer and the possible therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Carlson, L. E., Speca, M., Patel, K. D., & Goodey, E. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000074003.35911.41 · Cited by 773 · cited 1×
“(Carlson et al., 2003; Fairey et al., 2005; Stevinson et al., 2009).”
Chan, J. L., Heist, K., DePaoli, A. M., Veldhuis, J. D., & Mantzoros, C. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17490 · Cited by 697
Havel, P. J. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s143 · Cited by 626
Serum protein markers for early detection of ovarian cancer
Mor, G., Visintin, I., Lai, Y., Zhao, H., Schwartz, P., Rutherford, T., Yue, L., Bray-Ward, P., & Ward, D. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502178102 · Cited by 482
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K., Gordon, S., & Balkwill, F. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5023 · Cited by 411
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B.-N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 402
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Energy regulation and neuroendocrine–immune control in chronic inflammatory diseases
Straub, R. H., Cutolo, M., Buttgereit, F., & Pongratz, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02218.x · Cited by 382
Colomiere, M., Ward, A. C., Riley, C., Trenerry, M. K., Cameron-Smith, D., Findlay, J., Ackland, L., & Ahmed, N. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604794 · Cited by 320
Drug therapy for the management of cancer-related fatigue
Minton, O., Richardson, A., Sharpe, M., Hotopf, M., & Stone, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006704.pub3 · Cited by 283
Fairey, A. S., Courneya, K. S., Field, C. J., Bell, G. J., Jones, L. W., & Mackey, J. R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00566.2004 · Cited by 271
Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K., Vaidya, A., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 247
The role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 234
Mantovani, G., Macciò, A., Madeddu, C., Serpe, R., Massa, E., Dessì, M., Panzone, F., & Contu, P. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0153 · Cited by 231
Self-citationA Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
Kulbe, H., Chakravarty, P., Leinster, D. A., Charles, K. A., Kwong, J., Thompson, R. G., Coward, J. I., Schioppa, T., Robinson, S. C., Gallagher, W. M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2178 · Cited by 220
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer
Costanzo, E. S., Lutgendorf, S. K., Sood, A. K., Anderson, B., Sorosky, J., & Lubaroff, D. M. (2005) · Cancer · doi:10.1002/cncr.21147 · Cited by 217 · cited 1×
“However, several recent studies among cancer patients have found associations between depression, elevated levels of the proinflammatory cytokine and/or dysregulation of the neuroendocrine hormone cortisol (Costanzo et al., 2005).”
BackgroundWang, Y., Niu, X. L., Qu, Y., Wu, J., Zhu, Y. Q., Sun, W. J., & Li, L. Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.019 · Cited by 210
Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients
Lutgendorf, S. K., Weinrib, A. Z., Penedo, F., Russell, D., DeGeest, K., Costanzo, E. S., Henderson, P. J., Sephton, S. E., Rohleder, N., Lucci, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1978 · Cited by 200
Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice
Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., McFarland-Mancini, M. M., & Drew, A. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4375 · Cited by 199
Giuntoli, R. L., Webb, T. J., Zoso, A., Rogers, O. C., Diaz-Montes, T. P., Bristow, R. E., & Oelke, M. (2009) · PubMed · Cited by 199
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
Scambia, G., Testa, U., Benedetti Panici, P., Foti, E., Martucci, R., Gadducci, A., Perillo, A., Facchini, V, Peschle, C., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.71 · Cited by 198
The Origins of Cachexia in Acute and Chronic Inflammatory Diseases*
Delano, M. J., & Moldawer, L. L. (2006) · Nutrition in Clinical Practice · doi:10.1177/011542650602100168 · Cited by 197
IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
Lo, C.-W., Chen, M.-W., Hsiao, M., Wang, S., Chen, C.-A., Hsiao, S.-M., Chang, J.-S., Lai, T.-C., Rose-John, S., Kuo, M.-L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1496 · Cited by 193
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
Lane, D., Matte, I., Rancourt, C., & Piché, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-210 · Cited by 190
Monk, J. P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L. J., Otterson, G. A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2838 · Cited by 179 · cited 1×
“among patients with advanced cancer (Monk et al., 2006), but effects among patients with”
BackgroundPlante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r · Cited by 173
Managing Cancer-Related Anorexia/Cachexia
Mantovani, G., Macci??, A., Massa, E., & Madeddu, C. (2001) · Drugs · doi:10.2165/00003495-200161040-00004 · Cited by 168
Self-citationOvarian cancer creates a suppressive microenvironment to escape immune elimination
Yigit, R., Massuger, L. F. A. G., Figdor, C. G., & Torensma, R. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.019 · Cited by 168
van Crevel, R., Karyadi, E., Netea, M. G., Verhoef, H., Nelwan, R. H. H., West, C. E., & van der Meer, J. W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8228 · Cited by 162
Ferrandina, G., Lauriola, L., Zannoni, G. F., Fagotti, A., Fanfani, F., Legge, F., Maggiano, N., Gessi, M., Mancuso, S., Ranelletti, F. O., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf207 · Cited by 160
Mantovani, G., Macciò, A., Madeddu, C., Gramignano, G., Lusso, M. R., Serpe, R., Massa, E., Astara, G., & Deiana, L. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0538 · Cited by 157
Self-citationNutritional support in multimodal therapy for cancer cachexia
Bosaeus, I. G. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-007-0388-7 · Cited by 153
Mantovani, G., Macciò, A., Madeddu, C., Mura, L., Gramignano, G., Lusso, M. R., Mulas, C., Mudu, M. C., Murgia, V., Camboni, P., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.10143 · Cited by 151
Self-citationDiurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer
Weinrib, A., Sephton, S. E., DeGeest, K., Penedo, F. J., Bender, D., Zimmerman, B. M., Kirschbaum, C., Sood, A. K., Lubaroff, D. M., & Lutgendorf, S. K. (2010) · Cancer · doi:10.1002/cncr.25299 · Cited by 151
Macciò, A., Madeddu, C., Massa, D., Mudu, M. C., Lusso, M. R., Gramignano, G., Serpe, R., Melis, G. B., & Mantovani, G. (2005) · Blood · doi:10.1182/blood-2005-01-0160 · Cited by 144
Self-citationSaydmohammed, M., Joseph, D., & Syed, V. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22558 · Cited by 142
Scarlett, U. K., Cubillos‐Ruiz, J. R., Nesbeth, Y. C., Martinez, D. G., Engle, X. A., Gewirtz, A. T., Ahonen, C. L., & Conejo-Garcia, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0835 · Cited by 137
Selvendiran, K., Bratasz, A., Kuppusamy, M. L., Tazi, M., Rivera, B. K., & Kuppusamy, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24601 · Cited by 136
Macdonald, N. (2007) · PubMed · Cited by 134
Rosen, D. G., Mercado‐Uribe, I., Yang, G. S., Bast, R. C., Amin, H. M., Lai, R. L., & Liu, J. (2006) · Cancer · doi:10.1002/cncr.22293 · Cited by 133
Mantovani, G., Macci�, A., Madeddu, C., Mura, L., Gramignano, G., Lusso, M. R., Massa, E., Mocci, M., & Serpe, R. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0476-1 · Cited by 126
Self-citationCirculating Inflammation Markers and Risk of Epithelial Ovarian Cancer
Clendenen, T. V., Lundin, E., Zeleniuch‐Jacquotte, A., Koenig, K. L., Berrino, F., Lukanova, A., Lokshin, A. E., Idahl, A., Ohlson, N., Hallmans, G., et al. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1180 · Cited by 118
Cytokine regulation networks in the cancer microenvironment
Sheu, B., Chang, W.-C., Cheng, C.-Y., Lin, H., Chang, D.-Y., & Huang, S.-C. (2008) · Frontiers in bioscience · doi:10.2741/3152 · Cited by 116
Altinoz, M. A., & Korkmaz, R. (2004) · PubMed · Cited by 111
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
Physical Activity in Ovarian Cancer Survivors
Stevinson, C. D., Steed, H. L., Faught, W., Tonkin, K. S., Vallance, J. K., Ladha, A. B., Schepansky, A., Capstick, V. A., & Courneya, K. S. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e31819902ec · Cited by 103
Ferrandina, G., Ranelletti, F. O., Lauriola, L., Fanfani, F., Legge, F., Mottolese, M., Nicotra, M., Natali, P. G., Zakut, V. H., & Scambia, G. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6620 · Cited by 101
Macciò, A., Lai, P., Santona, M. C., et al. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.4974 · Cited by 93
Self-citationSeo, J. H., Jeong, K. J., Oh, W. J., Sul, H. J., Sohn, J. S., Kim, Y. K., Cho, D. Y., Kang, J., Park, C. G., & Lee, H. Y. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.023 · Cited by 90
Jeannin, P., Duluc, D., & Delneste, Y. (2011) · Immunotherapy · doi:10.2217/imt.11.30 · Cited by 84
Cell growth regulation in epithelial ovarian cancer
Bast, R. C., Boyer, C. M., Jacobs, I. J., et al. (1993) · Cancer · doi:10.1002/cncr.2820710426 · Cited by 83
Nowak, M., Głowacka, E., Szpakowski, M., Szyłło, K., Malinowski, A., Kulig, A., Tchórzewski, H., & Wilczyński, J. (2010) · PubMed · Cited by 77
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
Napoletano, C., Bellati, F., Landi, R., Pauselli, S., Marchetti, C., Visconti, V. V., Sale, P., Liberati, M., Rughetti, A., Frati, L., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00911.x · Cited by 76
Gavalas, N. G., Karadimou, A., Dimopoulos, M. A., & Bamias, A. (2010) · Journal of Immunology Research · doi:10.1155/2010/791603 · Cited by 76
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 75
STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843218 · Cited by 73
Macciò, A., Madeddu, C., Gramignano, G., Mulas, C., Sanna, E., & Mantovani, G. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0020 · Cited by 64
Self-citationA review of issues surrounding quality of life among women with ovarian cancer
Arriba, L. N., Fader, A. N., Frasure, H. E., & von Gruenigen, V. E. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.014 · Cited by 63
Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer
Yigit, R., Figdor, C. G., Zusterzeel, P. L. M., Pots, J. M., Torensma, R., & Massuger, L. F. A. G. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.026 · Cited by 62
Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6.
Rabinovich, A., Medina, L., Piura, B., Segal, S., & Huleihel, M. (2007) · PubMed · Cited by 60
Zhang, X., Liu, P., Zhang, B., Wang, A., & Yang, M. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.10.004 · Cited by 59
van der Zee, A. G. J., de Bruijn, H. W. A., Krans, M., Cuyper, E. M. D., Hollema, H., Limburg, P. C., Bijzet, J., & de Vries, E. G. E. (1995) · Cancer · doi:10.1002/1097-0142(19950215)75:4<1004::aid-cncr2820750416>3.0.co;2-g · Cited by 54
Interleukin‐6 and leptin as markers of energy metabolicchanges in advanced ovarian cancer patients
Macciò, A., Madeddu, C., Massa, D., Astara, G., Farci, D., Melis, G. B., & Mantovani, G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00408.x · Cited by 54
Self-citationMin, H., & Wei‐hong, Z. (2009) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2009.01045.x · Cited by 53
Mantovani, G., Macci�, A., Melis, G. B., Mura, L., Massa, E., & Mudu, M. C. (2000) · International Journal of Cancer · Cited by 51
Self-citationMantovani, G., Macciò, A., Pisano, M., Versace, R., Lai, P., Esu, S., Massa, E., Ghiani, M., Dessì, D., Melis, G. B., et al. (1997) · International Journal of Cancer · Cited by 45
Self-citationOxygenation inhibits ovarian tumor growth by down-regulating STAT3 and cyclin-D1 expressions
Selvendiran, K., Kuppusamy, M. L., Ahmed, S., Bratasz, A., Meenakshisundaram, G., Rivera, B. K., Khan, M., & Kuppusamy, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.4.12448 · Cited by 45
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Cubillos‐Ruiz, J. R., Rutkowski, M. R., & Conejo-Garcia, J. R. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10430 · Cited by 44
Molecular typing of epithelial ovarian carcinomas using inflammatory markers
Ali‐Fehmi, R., Semaan, A. Y., Sethi, S., Arabi, H., Bandyopadhyay, S., Hussein, Y. R., Diamond, M. P., Saed, G. M., Morris, R. T., & Munkarah, A. R. (2010) · Cancer · doi:10.1002/cncr.25588 · Cited by 41
Nowak, M., Klink, M., Głowacka, E., Sułowska, Z., Kulig, A., Szpakowski, M., Szyłło, K., & Tchórzewski, H. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02350.x · Cited by 39
Expression of soluble interleukin-6 receptor in malignant ovarian tissue
Rath, K. S., Funk, H. M., Bowling, M. C., Richards, W. E., & Drew, A. F. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.03.034 · Cited by 36
Takeda, A., Toda, T., Shinohara, S., Mogi, Y., & Matsui, N. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33918 · Cited by 34
Clarke, S. J., Smith, J., Gebbie, C., Sweeney, C. J., & Olszewski, N. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3025 · Cited by 26
Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer
Wertel, I., Nowicka, A., Rogala, E., & Kotarski, J. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.569902 · Cited by 14
Cited by
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis
Browning, L., Patel, M., Bring Horvath, E., Tawara, K., & Jorcyk, C. L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s179189 · Cited by 286
PRKCI promotes immune suppression in ovarian cancer
Sarkar, S., Bristow, C. A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S. Y., et al. (2017) · Genes & Development · doi:10.1101/gad.296640.117 · Cited by 93
Anuka, E., Gal, M., Stocco, D. M., & Orly, J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.003 · Cited by 60
Yan, K., Zhu, W., Yu, L., Li, N., Zhang, X., Liu, P., Chen, Q., Chen, Y., & Han, D. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.027 · Cited by 26
Metadata
- Authors
- Macciò, A., & Madeddu, C.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 58
- Issue
- 2
- Pages
- 133-147
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2127387778
- Cited by
- 295
- References
- 78
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.